Who We Are

At Apellis, we strive to be known for our compassion, revolutionary science, and contributions to humankind around the world. We are built on the core belief that we can develop life-changing medicines to address a range of serious and debilitating diseases by controlling the complement cascade, which is a part of the body’s immune system.

The Pursuit of Groundbreaking Science

Founded in 2009 by a small group of entrepreneurs, including a physician-scientist who is our CEO, Apellis was established with the ambition to become the first company to develop a targeted C3 therapy for serious diseases driven by complement. Controlling C3 was viewed as scientifically difficult, if not impossible by many, but the significant unmet needs of patients living with complement-driven diseases inspired our founders’ efforts.

In 2021, our unique approach of targeting C3 was validated with the FDA approval of Apellis’ first therapy. We also are leveraging this science to advance the first potential treatment for geographic atrophy, a leading cause of blindness around the world, and to potentially elevate the standard of care for several serious rare diseases. We believe we are just scratching the surface of what may be possible by controlling C3, the only target in the complement cascade that addresses all three pathways that can drive disease.

Bold at Our Core

Our company is formed by people who care, are fearless in the face of a challenge, love the work they do, and continually pursue the highest level of scientific integrity. These values guide every decision that we make as we aim to become a leader in the biotech industry that always puts patients first.


Our Responsibility

We care fiercely about the greater good of society and believe corporate responsibility is foundational to achieving our vision.

We strive to bring transformative medicines to patients, provide an engaging and inclusive workplace for our employees, minimize our impact on the environment, and always demonstrate integrity in our actions.

We recognize that we are early in our journey and there is much work to be done but are committed to becoming a sustainable company that delivers on its vision.

Read our inaugural Environmental, Social, and Governance (ESG) Report.